Poly(ε-caprolactone)

Polycaprolactone (PCL) Recent Market Intelligence Report

I. Price Dynamics

* Current Price: As of July 29, 2026, the domestic Chinese national-standard PCL market price remains stable at RMB 53,000 per ton, unchanged from the beginning of the year and holding at the upper end of the past 12-month range.
* Import Price: Premium medical-grade PCL is priced at RMB 8.00 per gram (approximately RMB 80,000 per ton), reflecting strong market demand for high-purity and customized products.
* Historical Volatility: In January 2026, the market price ranged between RMB 32,000–38,000 per ton—lower than the RMB 35,000–45,000/ton fluctuation range observed during 2023–2025—primarily driven by improved supply-demand balance and declining raw material costs.

II. Supply-Demand Relationship

* Capacity Expansion:
* China’s PCL production capacity surpassed 50,000 tons/year in 2025; over 40,000 tons of new capacity is planned for 2026, concentrated mainly in the East and South China regions, while the Southwest region is developing a differentiated layout leveraging green energy infrastructure.
* Juren New Materials—the world’s largest caprolactone producer—has established an integrated caprolactone derivatives capacity of 55,000 tons/year and plans to further extend into downstream PCL derivative applications via its publicly funded expansion projects.
* Production & Consumption:
* Actual output reached 39,000 tons by end-2025; apparent consumption stood at 42,000 tons, resulting in an import dependency rate of approximately 12%, concentrated primarily in high-purity medical-grade products.
* Regional Distribution:
* The East China region accounts for 58% of national PCL capacity; South China holds 22.9%; North China and Southwest China account for 10.4% and 8.3%, respectively.

III. Market Drivers

* Policy Support:
* China’s “Dual Carbon” strategy and the “14th Five-Year Plan for Biotechnology Development” explicitly support biodegradable materials such as PCL, with multiple provincial and municipal governments introducing dedicated subsidies and tax incentives.
* The National Medical Products Administration (NMPA) has included PCL in its Recommended List of High-Molecular Materials for Absorbable Medical Devices (Guiding Principles), driving a 47% year-on-year increase in Class III medical device registration submissions and accelerating import substitution.
* Market Demand:
* Medical Applications: Population aging and the widespread adoption of minimally invasive surgery are fueling demand for premium PCL products—including bone repair scaffolds and long-term sustained-release microspheres. In 2024, China’s surgical suture market reached approximately RMB 9.8 billion, growing 6.99% year-on-year; owing to its excellent biocompatibility and controllable degradation profile, PCL demand continues to rise in absorbable suture applications.
* Eco-Friendly Packaging: Regulatory mandates replacing conventional plastics have boosted PCL-based composite material penetration in frozen food packaging and express delivery bags to over 20%. The mandatory “National Standard for Green Express Packaging”, effective December 2025, stipulates that biodegradable materials must constitute no less than 35% of cold-chain packaging for fresh e-commerce logistics—making PCL the sole biodegradable base material meeting full cold-chain temperature control requirements due to its low-temperature resistance and superior puncture strength.
* 3D Printing: Demand for medical-grade PCL is growing at 30% annually, with emerging commercial applications expanding into flexible electronics and self-healing coatings.
* Industrial Applications: PCL-based adhesives and insulating materials are increasingly adopted in 5G base stations and new-energy vehicle battery components, propelling product upgrades toward higher value-added segments.

IV. Cost Dynamics

* Raw Material Prices: As of late November 2025, domestic cyclohexanone prices stood at RMB 6,575 per ton—a 27.88% year-on-year decline—further compressing PCL raw material costs.
* Domestication Rate Improvement: The domestic production share of ε-caprolactone (CL) is projected to rise from under 30% in 2025 to over 50% in 2026, with enterprises including Wanhua Chemical and Hualu Hengsheng accelerating CL project deployment—contributing to an estimated 15–20% reduction in PCL manufacturing costs.

V. Analysis & Outlook

* Price Trend:
* In the short term, PCL prices will remain stable at elevated levels, supported by balanced supply-demand dynamics and cost fundamentals. Although new capacity is gradually coming online, robust demand from high-end sectors—including healthcare and environmental protection—will continue narrowing the supply-demand gap.
* Long-term, with rising domestication rates and lower raw material costs, PCL prices are expected to trend downward steadily; however, premium medical-grade products will sustain pricing premiums.
* Market Structure:
* Domestic manufacturers are progressively displacing international giants—including BASF and Covestro—in the Chinese market through technological breakthroughs and scale expansion, positioning China as a core global supplier of biodegradable materials.
* Industry concentration will intensify, with leading enterprises broadening market share via technological and cost advantages, while SMEs pursue differentiation strategies to carve out niche positions.
* Application Expansion:
* PCL applications will continue expanding across medical, environmental, 3D printing, and industrial manufacturing domains—with particularly rapid growth anticipated in high-performance specialized scenarios.
* Breakthroughs in biocatalytic synthesis, nanocomposite modification, and other advanced technologies will drive PCL upgrades toward medical-grade and electronics-grade high-end products, making molecular design and composite engineering key competitive frontiers.